Patents by Inventor Theodore S. Widlanski

Theodore S. Widlanski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleotides and oligonucleotides preparable therefrom
    Patent number: 6117988
    Abstract: Analogues of RNA and DNA compounds contain a neutral, stereoregular linking group based on replacement of the phosphoryl with a sulfonyl group. Precursors to the analogues are also described, as are methods for preparing the precursors and analogues.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: September 12, 2000
    Assignee: Advanced Research & Technology Institute
    Inventor: Theodore S. Widlanski
  • Phosphatase/phosphodiesterase enzyme inhibitors and methods
    Patent number: 5714361
    Abstract: Described are preferred suicide inhibitors of phosphatase or phosphodiesterase enzymes, and methods for preparing halo enol phosphates which can serve as such suicide inhibitors.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: February 3, 1998
    Assignee: Indiana University Foundation
    Inventor: Theodore S. Widlanski
  • 3'-sulfonyl nucleoside compounds
    Patent number: 5536823
    Abstract: Analogues of RNA and DNA compounds contain a neutral, stereoregular linking group based on replacement of the phosphoryl with a sulfonyl group. Precursors to the analogues are also described, as are methods for preparing the precursors and analogues.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: July 16, 1996
    Assignee: Indiana University Foundation
    Inventor: Theodore S. Widlanski
  • Creatine analogs having antiviral activity
    Patent number: 5321030
    Abstract: The present invention relates to the use of analogs of creatine, such as cyclocreatine, as antiviral agents. Analogs of creatine can be used as antiviral agents against a variety of viruses, particularly DNA viruses, such as Herpes viruses (e.g., HSV-1, HSV-2, cytomegaloviruses, Varicella-Zoster virus) and adenovirus. The invention further relates to creatine analogs including four classes of creatine analogs selected as candidate antiviral compounds: (1) creatine analogs that can be phosphorylated by creatine kinase but differ in their phosphoryl group transfer potential, (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine, (3) creatine analogs which can act as irreversible inhibitors of creatine kinase, and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: June 14, 1994
    Assignee: Amira, Inc.
    Inventors: Rima Kaddurah-Daouk, James W. Lillie, Theodore S. Widlanski, Jonathan J. Burbaum, Craig J. Forsyth